Breadcrumb

Clinical Trials

NCI clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma

NCI and CCR researchers have played an instrumental role in identifying the first treatment approved for advanced alveolar soft part sarcoma. The immunotherapy drug atezolizumab (Tecentriq) was approved by the U.S. Food and Drug Administration for the treatment of adults and children two years of age and older with alveolar soft part sarcoma that has spread to other parts of the body or cannot be removed by surgery. The CCR Pediatric Oncology Branch provided treatment and care for all trial patients under 18 years old, making this the first approval for atezolizumab in children.

Read More